← All trials
NCT00477451
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2007
- Primary completion
- Apr 1, 2008
- Completion date
- Apr 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 49
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Alexza Pharmaceuticals, Inc.Lead sponsor
- Columbia UniversityOverall official - principal investigator
- State University of New York, BrooklynOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.